caa a22 4500 465735150 CHVBK 20180323111752.0 cr unu---uuuuu 170327e19900801xx s 000 0 eng 10.1007/BF00167071 doi (NATIONALLICENCE)springer-10.1007/BF00167071 A phase II study of diaziquone in children with recurrent or progressive primary brain tumors: A report from the Childrens Cancer Study Group [Elektronische Daten] [Lawrence Ettinger, Ning Ru, Mark Krailo, Kathleen Ruccione, William Krivit, G. Hammond] Summary: Seventy-five children with recurrent, progressive or metastatic primary brain tumors were treated with aziridinylbenzoquinone (AZQ; Diaziquone) at 9 mg/m2/day by 30-minute intravenous infusion for five days every three weeks. Sixty-six patients were evaluable for response by imaging studies. There were five partial responses and one complete response for a combined response rate of 9%. A complete response lasting for 35 + months occurred in one of twelve patients with metastatic or locally recurrent ependymoma. Objective responses were also seen in patients with primitive neuroectodermal tumors (PNET) (1/8), low-grade glioma (1/6), and primary central nervous system lymphoma (1/1). Stable disease of greater than six months duration was seen in patients with ependymoma, PNET and medulloblastoma. Profound and prolonged myelosuppression was the significant toxicity observed. As administered in this study, AZQ has marginal activity and severe toxicity. Kluwer Academic Publishers, 1990 AZQ nationallicence brain tumors nationallicence chemotherapy nationallicence Ettinger Lawrence University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick aut Ru Ning University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick aut Krailo Mark University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick aut Ruccione Kathleen University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick aut Krivit William University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick aut Hammond G. University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick aut Journal of Neuro-Oncology Kluwer Academic Publishers 9/1(1990-08-01), 69-76 0167-594X 9:1<69 1990 9 11060 https://doi.org/10.1007/BF00167071 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00167071 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Ettinger Lawrence University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick aut NATIONALLICENCE 700 1- Ru Ning University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick aut NATIONALLICENCE 700 1- Krailo Mark University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick aut NATIONALLICENCE 700 1- Ruccione Kathleen University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick aut NATIONALLICENCE 700 1- Krivit William University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick aut NATIONALLICENCE 700 1- Hammond G. University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick aut NATIONALLICENCE 773 0- Journal of Neuro-Oncology Kluwer Academic Publishers 9/1(1990-08-01), 69-76 0167-594X 9:1<69 1990 9 11060 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer